# Immix Biopharma (IMMX) — Earnings

IMMX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/immx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.22 |
| EPS estimate | −$0.16 |
| EPS surprise | −37.50% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 8, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1873835/000164117225022829/form10-q.htm) |

Immix Biopharma reported its Q2 2025 results on August 8, 2025. The company posted a loss of $0.22 per share, wider than the $0.16 loss analysts expected, a miss of 37.50%. A year earlier, in Q2 2024, the loss was $0.15 per share. No revenue was reported for the quarter, and none appears anywhere in the table.

The record is short and has gaps: seven quarters from Q3 2023 to Q2 2025, with Q4 2023 missing. Every quarter shown was a loss, ranging from $0.15 to $0.24 per share. The four quarters of 2024 add up to a loss of $0.80 per share. The first half of 2025 lost $0.37 per share, close to the $0.38 lost in the first half of 2024. Against estimates, results were mixed: two beats, two misses and three quarters exactly in line. The largest miss was Q3 2024, at 50.00%, and the largest beat Q1 2025, at 34.78%.

The table shows no report after Q2 2025. In the period covered, Immix reported second-quarter results in August and third-quarter results in mid-November. Newer figures will show whether the losses stay in the same range seen over the past two years.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 8, 2025 | −$0.16 | −$0.22 | -37.50% | — | — |
| Q1 2025 | May 8, 2025 | −$0.23 | −$0.15 | 34.78% | — | — |
| Q4 2024 | Mar 25, 2025 | −$0.25 | −$0.18 | 28.00% | — | — |
| Q3 2024 | Nov 12, 2024 | −$0.16 | −$0.24 | -50.00% | — | — |
| Q2 2024 | Aug 12, 2024 | −$0.15 | −$0.15 | 0.00% | — | — |
| Q1 2024 | May 9, 2024 | −$0.23 | −$0.23 | 0.00% | — | — |
| Q3 2023 | Nov 13, 2023 | −$0.23 | −$0.23 | 0.00% | — | — |

## Frequently Asked Questions

### When did Immix Biopharma (IMMX) last report earnings?

Immix Biopharma last reported on Aug 8, 2025, covering fiscal Q2 2025.

### Did IMMX beat earnings estimates?

No. Immix Biopharma reported EPS of −$0.22 for Q2 2025 against a −$0.16 estimate — a 37.50% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).